Jubilant Therapeutics Inc. administre une dose au premier patient de l’essai de phase I/II évaluant le JBI-802, un inhibiteur double de LSD1 et de HDAC6, chez des patients atteints de tumeurs solides avancées Deutschland – Deutsch USA – English France – Français
PBF Logistics Declares Quarterly Distribution of $0.30 per Unit and Announces First Quarter 2022 Earnings Results
LAWSUIT AGAINST DUNKIN’ BELIEVED TO BE FIRST ALLEGING LINK BETWEEN SEVERE CUSTOMER BURNS AND DEFECTIVE PAPER COFFEE-CUP CARRIER
Dstillery Launches ID-free Custom AI™ to Help Brands Reach Their Audiences Without Third-Party Cookies
COLOMBIAN AUTHOR AND CEO OF IVOICE COMMUNICATIONS ADRIANA ARISTIZÁBAL RELEASES THE SPANISH VERSION OF HER BOOK AT THE 34TH ANNUAL INTERNATIONAL BOOK FAIR HELD IN BOGOTÁ
Bausch Health Enters Into Arrangement Agreement with Bausch + Lomb Corporation in Connection with Previously Announced Proposed Separation
Ocean County Man Admits Illegally Possessing Short-Barreled Rifle, Silencer, and Fake Federal Identification Badges
